REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $320.53 million. The enterprise value is $414.81 million.
| Market Cap | 320.53M |
| Enterprise Value | 414.81M |
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 51.70 million shares outstanding. The number of shares has increased by 1.81% in one year.
| Current Share Class | 51.70M |
| Shares Outstanding | 51.70M |
| Shares Change (YoY) | +1.81% |
| Shares Change (QoQ) | +1.31% |
| Owned by Insiders (%) | 8.31% |
| Owned by Institutions (%) | 72.06% |
| Float | 43.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.61 |
| Forward PS | 1.33 |
| PB Ratio | 15.01 |
| P/TBV Ratio | 15.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 11.78.
| Current Ratio | 2.62 |
| Quick Ratio | 2.44 |
| Debt / Equity | 11.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.69 |
Financial Efficiency
Return on equity (ROE) is -196.43% and return on invested capital (ROIC) is -203.58%.
| Return on Equity (ROE) | -196.43% |
| Return on Assets (ROA) | -38.53% |
| Return on Invested Capital (ROIC) | -203.58% |
| Return on Capital Employed (ROCE) | -94.79% |
| Weighted Average Cost of Capital (WACC) | 11.86% |
| Revenue Per Employee | $236,717 |
| Profits Per Employee | -$781,704 |
| Employee Count | 371 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.09% in the last 52 weeks. The beta is 1.03, so REGENXBIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -33.09% |
| 50-Day Moving Average | 8.17 |
| 200-Day Moving Average | 10.41 |
| Relative Strength Index (RSI) | 41.53 |
| Average Volume (20 Days) | 2,111,133 |
Short Selling Information
The latest short interest is 7.14 million, so 13.80% of the outstanding shares have been sold short.
| Short Interest | 7.14M |
| Short Previous Month | 6.69M |
| Short % of Shares Out | 13.80% |
| Short % of Float | 16.58% |
| Short Ratio (days to cover) | 5.16 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $87.82 million and -$290.01 million in losses. Loss per share was -$5.60.
| Revenue | 87.82M |
| Gross Profit | -172.67M |
| Operating Income | -256.69M |
| Pretax Income | -290.01M |
| Net Income | -290.01M |
| EBITDA | -241.17M |
| EBIT | -256.69M |
| Loss Per Share | -$5.60 |
Balance Sheet
The company has $150.49 million in cash and $248.40 million in debt, with a net cash position of -$97.91 million or -$1.89 per share.
| Cash & Cash Equivalents | 150.49M |
| Total Debt | 248.40M |
| Net Cash | -97.91M |
| Net Cash Per Share | -$1.89 |
| Equity (Book Value) | 21.08M |
| Book Value Per Share | 0.41 |
| Working Capital | 115.41M |
Cash Flow
In the last 12 months, operating cash flow was -$233.78 million and capital expenditures -$2.63 million, giving a free cash flow of -$236.40 million.
| Operating Cash Flow | -233.78M |
| Capital Expenditures | -2.63M |
| Depreciation & Amortization | 15.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -236.40M |
| FCF Per Share | -$4.57 |
Margins
| Gross Margin | -196.61% |
| Operating Margin | -292.28% |
| Pretax Margin | -330.23% |
| Profit Margin | n/a |
| EBITDA Margin | -274.61% |
| EBIT Margin | -292.28% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.81% |
| Shareholder Yield | -1.81% |
| Earnings Yield | -91.51% |
| FCF Yield | -74.60% |
Analyst Forecast
The average price target for REGENXBIO is $23.82, which is 284.19% higher than the current price. The consensus rating is "Buy".
| Price Target | $23.82 |
| Price Target Difference | 284.19% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 31.23% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -5.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.84 |
| Piotroski F-Score | 1 |